Question to the Department for International Trade:

To ask the Secretary of State for International Trade, with reference to the European Commission press release entitled EU-U.S. trade talks: milestone reached in mutual recognition on pharmaceuticals, dated 11 July 2019, whether the recently agreed mutual recognition agreement between the US and EU will continue to apply to manufacturers of pharmaceuticals in the UK in the event of the UK leaving the EU without a deal.

All operational aspects of the EU-US mutual recognition agreement on conformity assessment (MRA) will continue to apply to the UK in the event of the UK leaving the EU without a deal.

The MRA signed between the UK and the US in Washington DC on 14 February 2019 provides continuity of the EU-US MRA, including the annex on Good Manufacturing Practice for pharmaceuticals. It is ready to enter into force as soon as the EU-US MRA ceases to apply to the UK, whether in the event of a deal or no-deal scenario.

For further information, please see https://www.gov.uk/government/collections/uk-us-mutual-recognition-agreement